Alasiri, Abdulrahman
Karczewski, Konrad J.
Cole, Brian
Loza, Bao-Li
Moore, Jason H.
van der Laan, Sander W.
Asselbergs, Folkert W.
Keating, Brendan J.
van Setten, Jessica
Funding for this research was provided by:
King Abdullah International Medical Research Center (400016184)
National Institutes of Health (LM010098, LM010098, LM010098, LM010098)
the Netherlands CardioVascular Research Initiative (CVON 2011/B019)
Innovative Medicines Initiative (116074, 116074)
Dutch Heart Foundation (2017T003)
Article History
Received: 4 March 2022
Accepted: 4 January 2023
First Online: 2 February 2023
Declarations
:
: UK Biobank (UKBB) had acquired ethics approval from the North West Multi-centre Research Ethics Committee, which covers the UK (approval number: 11/NW/0382) and had obtained informed consent from all participants. UKBB data used in this study were obtained under application ID 24711. Collection of the Genome of the Netherlands (GoNL) data was approved by the committee of GoNL and all necessary participant consent has been obtained. GoNL data used in this study were obtained under application ID 2021217.
: All participants provided written informed consent for their anonymized information to be used for health-related research purposes and the results thereof to be published.
: The authors declare that they have no competing interests. Dr. Sander W. van der Laan has received Roche funding for unrelated work.